...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Allergy >Geohelminth infections: a review of the role of IgE and assessment of potential risks of anti-IgE treatment.
【24h】

Geohelminth infections: a review of the role of IgE and assessment of potential risks of anti-IgE treatment.

机译：地蠕虫感染：IgE的作用综述以及抗IgE治疗的潜在风险评估。

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Geohelminth infections are major parasitic infections with a worldwide distribution. Immunoglobulin E (IgE) is considered to play a central role in protective immunity against these parasites although the evidence from experimental animal models infected with helminth parasites and treated with anti-IgE antibodies and from observational studies in human populations of the immunologic correlates of protective immunity against helminths do not support a critical role for IgE in mediating protection against helminths. Anti-IgE treatment of human allergic disorders using a humanized monoclonal IgE antibody (omalizumab, Xolair) has been approved for clinical use in the USA and Europe and there is concern that this treatment may be associated with increased morbidity in populations exposed to helminth infections. A recently published randomized controlled trial investigating the risk of geohelminth infections in allergic patients receiving omalizumab in Brazil has provided some evidence that omalizumab may not be associated with increased morbidity attributable to these parasites. This review examines the evidence for a role of IgE in protective immunity against helminth parasites, discusses the findings of the randomized controlled trial, assesses the potential risks and provides recommendations for anti-IgE treatment in groups of allergic patients with different exposure risks for helminth infections.
机译：蠕虫感染是主要的寄生虫感染，分布在世界各地。免疫球蛋白E（IgE）被认为在针对这些寄生虫的保护性免疫中起着核心作用，尽管来自感染蠕虫寄生虫并用抗IgE抗体治疗的实验动物模型的证据以及来自人群中保护性免疫免疫相关性的观察性研究的证据对抗蠕虫并不支持IgE在介导针对蠕虫的保护中起关键作用。在美国和欧洲，已批准使用人源化单克隆IgE抗体（奥马珠单抗，Xolair）的抗IgE治疗人类过敏性疾病，并已在美国和欧洲进行临床应用，令人担忧的是，这种治疗可能与感染蠕虫感染人群的发病率增加有关。最近发表的一项随机对照试验研究了在巴西接受omalizumab的变态反应患者中的蠕虫感染风险，该研究提供了一些证据表明omalizumab可能与这些寄生虫引起的发病率增加无关。这篇综述检查了IgE在对蠕虫寄生虫的保护性免疫中的作用的证据，讨论了随机对照试验的结果，评估了潜在风险，并为具有不同暴露风险的过敏性患者群体中的抗IgE治疗提供了建议， 。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号